 |
|
|
|
 |
|
|
Pazinaclone
|
|
Pazinaclone
|
| Systematic (IUPAC) name |
| 2-(7-chloro-1,8-naphthyridin-2-yl)-3-[2-(1,4-dioxa-8- azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3H-isoindol-1-one |
| Identifiers |
| CAS number |
103255-66-9 |
| ATC code |
? |
| PubChem |
59743 |
| Chemical data |
| Formula |
C25H23ClN4O4 |
| Mol. mass |
478.928 g/mol |
| Pharmacokinetic data |
| Bioavailability |
? |
| Metabolism |
? |
| Half life |
? |
| Excretion |
? |
| Therapeutic considerations |
| Pregnancy cat. |
?
|
| Legal status |
|
| Routes |
? |
Pazinaclone (DN-2327) is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs. Other cyclopyrrolone drugs include zopiclone and eszopiclone.
Pazinaclone has a very similar pharmacological profile to the benzodiazepine family of drugs including sedative and anxiolytic properties, but with less amnestic effects,[1] and at low doses it is a relatively selective anxiolytic, with sedative effects only appearing at higher doses.[2]
Pazinaclone produces its sedative and anxiolytic effects by acting as a partial agonist at GABAA benzodiazepine receptors, although pazinaclone is more subtype-selective than most benzodiazepines.[3]
References
- ^ Wada T, Fukuda N. Effect of a new anxiolytic, DN-2327, on learning and memory in rats. Pharmacology, Biochemistry and Behavior. 1992 Mar;41(3):573-9.
- ^ Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology (Berlin). 1995 Oct;121(4):442-50.
- ^ Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opinion on Investigational Drugs. 2005 May;14(5):601-18.
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pazinaclone". A list of authors is available in Wikipedia.
|
|
|
|
|
|
Top